XORTX Therapeutics (XRTX) Long-Term Debt Issuances (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Long-Term Debt Issuances came in at $17132.0 in Q1 2026, down 98.57% YoY from $1.2 million in Q1 2025, and down 98.57% on a QoQ basis from $1.2 million in Q4 2025.
XORTX Therapeutics (XRTX) Long-Term Debt Issuances (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Long-Term Debt Issuances data on file, last reported at $17132.0 in Q1 2026.
- Quarterly Long-Term Debt Issuances fell 98.57% year-over-year to $17132.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $702823.0 (down 41.43% YoY) and the FY2025 annual result came in at $1.2 million, changed 0.0% from the prior year.
- Long-Term Debt Issuances retreated to $17132.0 in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $1.3 million in Q1 2022 to a low of -$6210.0 in Q1 2023.
- A 5-year average of $613795.9 and a median of $471391.8 in 2022 frame the typical range for Long-Term Debt Issuances.
- Annual changes were most pronounced in 2022 — Long-Term Debt Issuances soared 6843.11% — and 2023, when it tumbled 100.49%.
- Tracing XRTX's Long-Term Debt Issuances over 5 years: stood at $180630.0 in 2022, then jumped by 79.06% to $323441.0 in 2023, then surged by 58.07% to $511271.0 in 2024, then jumped by 134.71% to $1.2 million in 2025, then tumbled by 98.57% to $17132.0 in 2026.
- The last three Long-Term Debt Issuances figures came in at $17132.0 (Q1 2026), $1.2 million (Q4 2025), and $111028.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 17,132.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,132.00 |
| Mar 31, 2026 | 17,132.00 |
| Dec 31, 2025 | 1.20 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 111,028.00 |
| Sep 30, 2025 | 111,028.00 |
| Jun 30, 2025 | 92,594.00 |
| Jun 30, 2025 | 92,594.00 |
| Mar 31, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 511,271.00 |
| Dec 31, 2024 | 511,271.00 |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 48,104.00 |
| Jun 30, 2024 | 48,104.00 |
| Mar 31, 2024 | 157,097.00 |
| Mar 31, 2024 | 157,097.00 |
| Dec 31, 2023 | 323,441.00 |
| Dec 31, 2023 | 323,441.00 |